KoBioLabs

KoBioLabs EV/EBIT

EV/EBIT (Enterprise Value to EBIT) of KoBioLabs (348150.KQ) as of Oct 25, 2026.

EV/EBIT

-

Last updated:

EV/EBIT (Enterprise Value to EBIT) of KoBioLabs is 2026 - . EV/EBIT (Enterprise Value to EBIT) of KoBioLabs was 2025 - . It decreases by % lower compared to the previous year.

The EV/EBIT history

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

KoBioLabs Stock analysis

What does KoBioLabs do? KoBioLabs Inc., headquartered in Seoul, South Korea, operates in the Health Care sector, specializing in biotechnology. The company focuses on research and development of the microbiome, developing products such as Bioviom and Queens henna FOODOLOGY, as well as new microbiome drugs. It provides commissioned research services and sells its products domestically and internationally. Listed on 18 November 2020, KoBioLabs is active in both domestic and overseas markets. KoBioLabs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about KoBioLabs stock

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) KoBioLabs since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s KoBioLabs with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — KoBioLabs

All Key Metrics — KoBioLabs